A cost-benefit analysis of the life-prolonging effect of nonsteroidal anti-inflammatory drugs for persons with dementia and pain

Robert J. Brent

Applied Economics, 2025, vol. 57, issue 45, 7350-7361

Abstract: Persons with dementia are more susceptible to pain. If they take Nonsteroidal Anti-Inflammatory Drugs (NSAID) as pain relievers, the policy question is whether these medicines will be socially worthwhile. In this paper, a Cost-Benefit Analysis (CBA) was undertaken of the NSAID to see whether their benefits outweigh the costs for elderly persons with dementia. To construct the benefits, a Quality Adjusted Life Year was used as the intervention output, which was then converted into monetary terms using the Value of a Statistical Life Year. Using estimates based on a large, US national panel data set, the CBA found that the NSAID generated positive net-benefits. It was possible to re-evaluate all the prior dementia interventions that were based on the same data set, using the same methods as for the NSAID CBA. By comparing the NSAID results with those from the other alternative dementia interventions one can establish public funding priorities.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1080/00036846.2024.2388312 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:applec:v:57:y:2025:i:45:p:7350-7361

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/RAEC20

DOI: 10.1080/00036846.2024.2388312

Access Statistics for this article

Applied Economics is currently edited by Anita Phillips

More articles in Applied Economics from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().